A retrospective study to identify predictors of response and to assess the impact radiotherapy might have on duration of response in patients treated with Immune checkpoint blockade in the treatment of advanced Non-small cell lung cancer
Latest Information Update: 02 Sep 2021
At a glance
- Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Carcinoma; Large cell carcinoma; Neuroendocrine carcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Pharmacodynamics; Therapeutic Use
- 02 Sep 2021 New trial record